1. Scrip

Regeneron's Evkeeza Approved For Ultra-Rare Genetic High Cholesterol – And Priced To Match

 
• By Jessica Merrill

Evkeeza is the first ANGPTL3 approved by the FDA; Regeneron scientists discovered the angiopoetin gene family.

Black Swan Event
Regeneron's Evkeeza is approved for an ultra-rare disease • Source: Shutterstock

Regeneron Pharmaceuticals, Inc. will target Evkeeza (evinacumab-dgnb) to an ultra-rare patient population with homozygous familial hypercholesterolemia (HoFH) and price it in the range that has become commonplace for drugs for ultra-rare conditions. The wholesale acquisition cost (WAC) in the US is based on weight but is expected to be approximately $450,000 per year on average, the firm said.

The US Food and Drug Administration approved Evkeeza for patients 12 and older with HoFH as an adjunct to other LDL cholesterol-lowering therapies on 11 February, under a priority review

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.